Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 53

Related Articles by Review for PubMed (Select 11744068)

1.

Yohimbine: a clinical review.

Tam SW, Worcel M, Wyllie M.

Pharmacol Ther. 2001 Sep;91(3):215-43. Review.

PMID:
11744068
3.

Yohimbine in erectile dysfunction: the facts.

Morales A.

Int J Impot Res. 2000 Mar;12 Suppl 1:S70-74. Review.

PMID:
10845767
4.

Yohimbine in erectile dysfunction: would an orphan drug ever be properly assessed?

Morales A.

World J Urol. 2001 Aug;19(4):251-5. Review.

PMID:
11550783
5.

New treatment options for erectile dysfunction in patients with diabetes mellitus.

Basu A, Ryder RE.

Drugs. 2004;64(23):2667-88. Review.

PMID:
15537369
6.

Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.

Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R.

Andrologia. 2006 Feb;38(1):1-12. Review.

PMID:
16420236
7.

Future options for combination therapy in the management of erectile dysfunction in older men.

Sommer F, Engelmann U.

Drugs Aging. 2004;21(9):555-64. Review.

PMID:
15260511
8.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
9.

Update on oral treatments for male erectile dysfunction.

Kalsi JS, Kell PD.

J Eur Acad Dermatol Venereol. 2004 May;18(3):267-74. Review.

PMID:
15096134
10.

Erectile dysfunction: oral pharmacotherapy options.

Vitezic D, Pelcic JM.

Int J Clin Pharmacol Ther. 2002 Sep;40(9):393-403. Review.

PMID:
12358156
11.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
12.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
13.

PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.

Rosen RC, McKenna KE.

Annu Rev Sex Res. 2002;13:36-88. Review.

PMID:
12836729
14.

Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.

Miner M, Rosenberg MT, Perelman MA.

Clin Ther. 2006 Jan;28(1):13-25. Review.

PMID:
16490576
15.

[Yohimbine in therapy of erectile dysfunction].

Pittler MH.

Fortschr Med. 1998 Jan 20;116(1-2):32-3. Review. German.

PMID:
9522535
17.

Moclobemide: therapeutic use and clinical studies.

Bonnet U.

CNS Drug Rev. 2003 Spring;9(1):97-140. Review.

PMID:
12595913
18.

5-alpha reductase inhibitors and erectile dysfunction: the connection.

Erdemir F, Harbin A, Hellstrom WJ.

J Sex Med. 2008 Dec;5(12):2917-24. doi: 10.1111/j.1743-6109.2008.01001.x. Review.

PMID:
19090946
19.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

20.

Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.

Gales BJ, Gales MA.

Ann Pharmacother. 2008 Jan;42(1):111-5. Epub 2007 Dec 19. Review.

PMID:
18094344
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk